What are the two August trials focused on COVID-19 patients?

The two August trials focused on COVID-19 patients are ACTIV-2 and ACTIV-3. These trials are part of the ACTIV (Accelerating COVID-19 Therapeutic Interventions and Vaccines) initiative, which was established to streamline the research and development of COVID-19 therapies.

ACTIV-2 is particularly important as it evaluates treatments for patients with mild to moderate COVID-19 who are at high risk of progressing to severe disease. It aims to find out how effective antiviral drugs or other therapies can be in preventing severe outcomes in these patients.

ACTIV-3, on the other hand, focuses on hospitalized patients with COVID-19. This trial compares the effectiveness of several treatments to identify the best therapeutic options for patients who require hospitalization, which is critical for managing severe cases of the disease.

Both of these trials are essential in contributing to the overall understanding of COVID-19 treatment strategies and play a crucial role in the ongoing effort to combat the pandemic.